Luspatercept
Thalassemia
Celgeneprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Thalassemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deferasirox Novartis Pharmaceuticals | Phase 4 | BBB |
Fludarabine Memorial Sloan Kettering Cancer Center | Phase 2/3 | BB |
Hydroxyurea Riphah International University | Phase 4 | BB |
Etavopivat Novo Nordisk A/S | Phase 3 | BB |
Busulphan University of California, San Francisco | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
Luspatercept is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →